Posted on 18/06/2009 in Pharmaceutical Company Product News Takeda has further enhanced its portfolio by launching two new dose strengths of Blowpress Plus.
Now available in Germany are fixed-dose combinations of 32 mg candesartan with either 25 mg and 12.5 mg of hydrochlorothiazide.
The additional measurements are intended to be used for patients with essential hypertension whose blood pressure is not adequately controlled by 32 mg candesartan or hydrochlorothiazide monotherapy.
Further introductions of the new doses are expected in other major European markets and the company has so far been granted marketing approval in Spain, Portugal and Austria.
Chief executive of Takeda Pharmaceuticals Europe Erich Brunn explained the Blowpress group of products is the company's largest selling franchise across the continent.
"The new doses can provide additional blood pressure reduction to hypertensive patients who need more than monotherapy alone," he said.
Earlier this month, the firm announced it had reviewed its development strategy for the marketing authorisation applications for the investigational compounds alogliptin and alogliptin/actos (pioglitazone HCl) in Europe.Other news stories from 18/06/2009
Read more in the Zenopa News Archive
How this news is generated
|
